Indian Pacing Electrophysiol. J.


   ISSN  0972-6292

Home Page Current Issue List of Editors

Indian Pacing Electrophysiol. J. 2003;3(3):148-156

Review Article


Download PDF 609 KB  

Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia

Julia H. Indik, MD PhD and Frank I. Marcus, MD

Sarver Heart Center, University of Arizona, Tucson AZ

This paper has been republished in the First International Symposium on Arrhythmogenic Right Ventricular Dysplasia

Address for correspondence: Dr. Julia H. Indik, MD, PhD, Sarver Heart Center, 1501 N. Campbell Avenue
Tucson, AZ 85724-5037.
E-mail: jindik@email.arizona.edu

Abstract

            Arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) is characterized by the patchy replacement of myocardium by fatty or fibrofatty tissue. These changes lead to structural abnormalities including right ventricular enlargement and wall motion abnormalities that can be detected by echocardiography, angiography, and cine MRI. ARVC/D is a genetically heterogeneous disorder, since it has been linked to several chromosomal loci. Myocarditis may also be a contributing etiological factor. Patients are typically diagnosed during adolescence or young adulthood. Presenting symptoms are generally related to ventricular arrhythmias. Concern for the risk of sudden cardiac death may lead to the implantation of an intracardiac defibrillator. An ongoing multicenter international registry should further our understanding of this disease.

Introduction

            Arhythmogenic right ventricular cardiomypathy/dysplasia (ARVC/D) is a disorder in which the right ventricular myocardium is interspersed with fatty or fibrofatty tissue. This pathological process principally affects the right ventricle, but in advanced cases can lead to biventricular involvement. Linkage analysis has identified several loci on different chromosomes, indicating this disease is genetically heterogeneous. Specific mutations have been identified in the genes for desmoplakin1, plakoglobin2 and the ryanodine receptor gene3. The predominant presenting symptoms are due to ventricular arrhythmias, including palpitations, sustained ventricular tachycardia, or uncommonly, sudden cardiac death. Although ARVC/D is an unusual disorder, it has been described as the most common cause of sudden death in young athletes under the age of 35 in the Veneto area in Italy4 . Heart failure is infrequent but may occur due to severe right or biventricular enlargement.

a) Structural Abnormalities and Pathophysiology

            Anatomically, ARVC/D is characterized by replacement of myocardium with fatty and fibrous tissue that primarily affects the epicardium and the mid-myocardium, with relative sparing of the endocardium (Figure 1 and 2). This process most commonly affects the posterior and inferior areas of the right ventricular inflow tract adjacent to the tricuspid valve5, but it also affects the anterior infundibulum and the apex, thus forming what is known as the "triangle of dysplasia"6. Loss of myocardium may result in aneurysm formation, commonly in the basal inferior wall, underneath the tricuspid valve7. Fibro-fatty replacement occurs in a segmental, patchy fashion and adjacent areas, particularly, the septum, are generally spared. Therefore, endomyocardial biopsies, which usually are performed from septal tissue, may be non-diagnostic. ARVC/D is distinguished from Uhl's anomaly, a congenital disorder in which right ventricular myocardium is absent, resulting in a paper-thin right ventricular wall8,9. Recently, apoptotic cells have been reported in endomyocardial biopsy specimens10,11,12,13. It is unknown how the apoptotic pathway may be initiated in ARVC/D, but may relate to altered intracellular calcium concentration1. Inflammatory infiltrates consisting of lymphocytes may also be found on biopsy specimens, suggestive of a focal myocarditis, and may explain sporadic cases of ARVD/C.

Figure 1: In ARVC/D there is progressive fibro-fatty replacement of the myocardium with thinning and enlargement of the RV wall. In this specimen there is gross fatty infiltration seen in a portion of the RV wall.


Figure 2: Trichrome staining shows areas of mature fibrosis (F) and adipose tissue (A) within the epicardial (Epi) and mid-myocardial zones, with remaining small clusters of myocytes (Myo) near the endocardial edge (Endo).


            Diffuse hypokinesis or regional wall motion abnormalities of the right ventricle can be seen with contrast ventriculography, considered to be the most reliable test to assess structural abnormalities. RV angiography should be performed in four views: RAO 30, LAO 60, AP and lateral. Affected areas will show hypokinesis, akinesis, or dyskinesis. Wall motion abnormalities can also be observed by echocardiography but particular attention must be focussed on imaging the basal posterior and inferior walls near the tricuspid valve5,14. MRI is emerging as a useful non-invasive tool to identify morphologic abnormalities such as myocardial fat, right ventricular chamber size and shape, and wall motion abnormalities with newer cine techniques. However, with conventional MR technology, the identification of myocardial fat was not found to be a reliable predictor of the presence of ARVC/D15.

b) Electrocardiographic Abnormalities

            Electrocardiographic changes include inverted T waves in the right precordial leads beyond V1 (Figure 3) in the absence of right bundle branch block16,17. Right ventricular late potentials in the form of epsilon waves may be found on the routine 12 lead ECG. If not present overtly, they may be identified by recording the ECG at double standard speed (50mm/sec) and amplitude (20mm/mV) and utilizing a 40 Hz filter5 (Figure 4) . Evidence of right ventricular parietal block is a QRS duration that is longer in the right (leads V1, V2 and V3) than in the left (V4, V5, V6) precordial leads. Suggested parameters to verify this include a localized QRS duration greater than 110ms in the right precordial leads, or a maximum QRS duration in leads V1, V2 or V3 or more than 25ms above the QRS duration in lead V6 in the presence of incomplete or complete right bundle branch block18. The signal averaged electrocardiogram is often abnormal and supports the diagnosis of ARVC/D, but if normal, does not exclude the diagnosis. The sensitivity of the signal averaged electrocardiogram can be improved by using a 25 Hz high pass filter and paying particular attention to the Z lead19.

Click here to view a larger image (170 kb)

Figure 3: This ECG from a patient with ARVC/D shows T wave inversion throughout the precordial leads.

 

Click here to view a larger image (109 kb)

Figure 4: Epsilon waves, representing right ventricular late potentials, can be brought out by recording the ECG at double speed (50mm/s), double amplitude (20mm/mV), and a 40 Hz filter. Here, epsilon waves are evident as small, notched deflections just after the QRS in lead V1 (arrows).


c) Arrhythmias

            The ventricular arrhythmias generally arise from the right ventricle, and therefore have a left branch block morphology. Right ventricular outflow tract tachycardia (RVOT), must be excluded as this diagnosis carries a benign prognosis and is not hereditary5 . RVOT tachycardia has a left bundle branch block morphology. The QRS points to the right and inferior (positive in leads II, III, AVF and negative in AVL); this morphology can also be seen in ventricular tachycardia due to ARVC/D. Patients with ARVC/D may also experience supraventricular arrhythmias20 including atrial flutter21,22,23.

d) Genetics

            Thirty to fifty percent of patients with ARVC/D will have evidence of familial disease25,26. The variable clinical expression and course is believed to be at least in part due to genetic heterogeneity. Inheritance is autosomal dominant, with the exception of Naxos disease, which is autosomal recessive. Linkage analysis in families with ARVD has revealed several loci for this disorder on chromosomes 1, 2, 3, 10, 14, and 1726,27,28,29,30,31(see Table 1). The mutation for ARVD8 has been identified in a gene for desmoplakin on chromosome 6, a component of desmosomes that are cellular adhesion proteins responsible for cellular binding1. This is the first gene identified to cause a major form of the disease, with autosomal dominant inheritance. The locus on chromosome 1 leads to a form of ARVC/D that is notable for exertional polymorphic, instead of monomorphic, ventricular tachycardia3,32 and has been further identified to encode a cardiac ryanodine receptor gene that is responsible for calcium release from the sarcoplasmic reticulum. This genetic mutation has also been implicated in familial catecholaminergic polymorphic ventricular tachycardia33,34. Naxos disease discovered on the Greek island, Naxos, is characterized by palmoplantar keratosis and woolly hair in addition to RV dysplasia. Naxos disease has been mapped to chromosome 17 involving a mutation in the gene that encodes plakoglobin, a component of desmosomes and adherens junctions responsible for maintaining tight adhesions between cells2. Another mutation in the gene for desmoplakin that also causes an autosomal recessive syndrome with woolly hair and a dilated left ventricle has been reported in patients from Ecuador35. Therefore, ARVD can result from a variety of genetic mechanisms, and in particular, appears to be a disorder of proteins involved in cellular adhesion and calcium release.

Table 1
ARVC/D Types
 

Type Chromosomal Locus Genetic Mutation
ARVD1 14q23-q24  
ARVD2 1q42-q43 Mutation in the ryanodine receptor, type 2 (RYR2)
ARVD3 14q12-q22  
ARVD4 2q32.1-q32.3  
ARVD5 3p23  
ARVD6 10p14-p12  
ARVD7 10q22.3  
ARVD8 6p24 Mutation in desmoplakin
Naxos Disease 17q21 Mutation in plakoglobin; woolly hair and keratoderma

ARVD types 1 through 8 are inherited as an autosomal dominant condition, while in Naxos disease the inheritance is autosomal recessive.
 

            Not all cases of ARVD are inherited since mutations may occur sporadically. Nonetheless, because of the genetic basis for this disorder, it is recommended that first degree relatives of ARVD patients be screened with an ECG and echocardiogram5. Other non-invasive tests to identify affected family members include signal-averaged ECG, Holter monitor and exercise stress testing.

Other Contributory Factors

            A large number of ARVC/D patients are noted to be athletes, and sudden cardiac death is more likely during exertion4. Athletic activity, possibly through stretch of myocardial fibers or elevated catecholamines may accelerate the degeneration of the ventricular myocardium and leads to ventricular arrhythmias. Also in support of the importance of other etiologic factors are the reports of Coxsackie virus B3 biopsy specimens36, and recently, enterovirus and adenovirus by polymerase chain reaction in 7 of 12 specimens from sporadic cases37. This raises the possibility that the myocardium in ARVD is particularly vulnerable to inflammatory processes. A superimposed myocarditis could result in lymphocytic infiltrates and fibrofatty replacement of the myocardium38,39. It is not known whether the detection of viral DNA or RNA indicates that right ventricular cardiomyopathy is a result of viral myocarditis or this cardiomyopathy predisposes the heart to viral infection. This process may only affect the RV, but can affect both ventricles as well. Patients with left ventricular involvement tend to be older and more symptomatic from both arrhythmias and heart failure, consistent with the view that the disease is progressive40.

            Since there is no single "gold standard" diagnostic test to reliably verify this condition, a combination of diagnostic criteria have been established by the Task Force of the Working Group on Myocardial and Pericardial Disease41. Major criteria include demonstration of severe wall motion abnormalities, fibrofatty replacement by biopsy, epsilon waves and family history of histologically confirmed disease. Minor criteria include milder alterations of ventricular function, inverted T waves in the right precordial leads, late potentials, ventricular tachycardia with left bundle branch morphology or frequent premature ventricular complexes (>1000 PVCs in a 24 hour period), or family history of suspected or clinically diagnosed ARVC/D. A diagnosis can then be made if at least two major, 1 major and 2 minor, or 4 minor criteria from different categories are fulfilled41.

            A prospective study of the course of disease in 37 affected families with 365 relatives in Italy showed that 41% could be diagnosed with certainty to have ARVC/D while in another 11% the diagnosis was uncertain42. Patients were diagnosed mostly during adolescence and early adulthood. After a mean follow-up of 8.5 years, an additional 15 subjects developed structural abnormalities or ventricular arrhythmias. In an evaluation of relatives of 67 ARVC/D patients in the United Kingdom, 28% of patients had relatives that satisfied the Task Force criteria, but another 20% had relatives with only minor ECG, echo or Holter abnormalities suggestive of early or mild disease43. Thus familial disease may have been present in up to 48% of index cases, which is plausible for a disease with autosomal dominant inheritance. It has been suggested by these authors that the standard diagnostic criteria should be modified to identify ARVC/D in relatives of patients with confirmed disease if they satisfy any one of the following abnormalities: i) T-wave inversion in the precordial leads ii) abnormal SAECG iii) ventricular tachycardia with left bundle branch morphology during ECG, Holter monitoring or exercise testing iv) greater than 200 PVCs in a 24 hour period or v) any mild echocardiographic abnormalities such as RV dilatation with preserved LV function42 .

Treatment/Management

            Therapy with beta blockers44, sotalol44 or amiodarone45 may be effective in suppressing ventricular arrhythmias and possibly in preventing sudden cardiac death. Implantation of an ICD may also be indicated to prevent sudden death. Catheter ablation of ventricular tachycardia may be useful in patients with refractory symptoms despite antiarrhythmic therapy. However, ventricular arrhythmias may recur from other areas. Patients should also be advised not to perform vigorous exercise or engage in competitive sports. Surgical disarticulation of the right ventricular free wall from its attachments to the left ventricle and septum can prevent the electrical propagation of ventricular arrythmias from the right to the left ventricle46,47. This was an effective means to prevent sudden death prior to the availability of the ICD, but resulted in severe right ventricular failure. Management of heart failure includes standard medical therapy with consideration of heart transplantation if severe ventricular, especially biventricular, dysfunction is present.

            It is important to emphasize that risk factors for sudden death are not well characterized. A history of syncope, right or left ventricular abnormalities seen on radionuclide angiography and QRS dispersion greater than 40ms are independent predictors of sudden death48. However, the absence of these factors cannot provide absolute assurance that a patient or relative is free of risk. The diverse phenotypic expression of ARVC/D is still being appreciated as new genetic loci are discovered. Furthermore, the risk of sudden death is probably variable among different types of ARVC/D. In Newfoundland, Canada, ARVD5 was reported to cause sudden death in 44% of affected males, while females had a more benign course with no sudden deaths49. Thus, determining prognosis is complicated by the genetic heterogeneity of this disorder.

            It is unclear how to advise family members of individuals that have died suddenly with ARVD. The eight-year actuarial probability of developing ventricular arrhythmias in asymptomatic family members with normal echocardiograms was found to be 3%, with no sudden deaths50. The potential risks associated with the implantation and long-term management of an intracardiac defibrillator in family members with suspected disease but minimal right ventricular dysfunction may far outweigh its potential benefits. Counseling of family members needs to be individualized.

            The Multidisciplinary Study of Right Ventricular Dysplasia is a multicenter study funded by the National Institutes of Health and National Heart, Lung, and Blood Institutes that is enrolling patients with a recent diagnosis of ARVC/D into a North American registry. A large registry of patients is needed to answer important questions related to diagnosis of the disorder, in particular in family members, as well as clinical management of affected patients and risk stratification for sudden death. This study will also facilitate genetic research to identify other specific mutations and their role in the pathogenesis of this disease51,52.

Acknowledgment

            We thank Dr. Richard Sobonya for preparation of the gross and microscopic pathology images.


References

1. Rampazzo A. Nava A. Malacrida S. Beffagna G. Bauce B. Rossi V. Zimbello R. Simionati B. Basso C. Thiene G. Towbin JA. Danieli GA. Mutation in human desmoplakin domain binding to plakoglobin causes a dominant form of arrhythmogenic right ventricular cardiomyopathy. American Journal of Human Genetics. 2002;71:1200-6

2. McKoy G. Protonotarios N. Crosby A. Tsatsopoulou A. Anastasakis A. Coonar A. Norman M. Baboonian C. Jeffery S. McKenna WJ. Identification of a deletion in plakoglobin in arrhythmogenic right ventricular cardiomyopathy with palmoplantar keratoderma and woolly hair (Naxos disease).
Lancet 2000; 355:2119-24.

3. Tiso N, Stephan DA, Nava A et al. Identification of mutations in the cardiac ryanodine receptor gene in families affected with arrhythmogenic right ventircular cardiomyopathy type 2 (ARVD2). Hum Mol Genet 2001; 10: 189-194.

4.  Corrado D, Thiene G, Nava A, Rossi L, Pennelli N. Sudden death in young competitive athletes: clinicopathologic correlations in 22 cases. Am J Medicine 1990; 89: 588-596.

5.  Marcus FI. Arrhythmogenic right ventricular dysplasia. Cardiac Electrophys Rev 1999; 3:205-206.

6. Marcus FI, Fontaine GH, Guiraudon G, Frank R, Laurenceau JL, Malergue C, Grosgogeat Y. Right ventricular dysplasia: a report of 24 adult cases. Circulation 1982; 65: 384-398.

7. Thiene G, Basso C, Danieli G, Rampazzo A, Corrado D, Nava A. Arrhythmogenic right ventricular cardiomyopathy. A still underrecognized clinic entity. Trends Cardiovasc Med 1997; 7:84-90.

8. Gerlis LM, Schmidt-Ott SC, Ho Sy, Anderson RH. Dysplastic conditions of the right ventircular myocardium: Uhl's anomaly versus arrhythmogenic right ventircualr dysplasia. Br Heart J 1993; 69:142-150.

9.  Fontaine G, Fontaliran F, Frank R. Arrhythmogenic right ventricular cardiomyopathies. Clinical forms and main differential diagnoses. Circulation. 1998; 97:1532-1535.

10.  Danieli GA and Rampazzo A. Genetics of arrhythmogenic right ventricular cardiomyopathy. Curr Opin in Card 2002; 17:218-221.

11.  Kavantzas NG, Lazaris AC, Agapitos EV et al. Histological assessment of apoptotic cell death in cardiomyopathies. Pathology 2000; 32: 176-180.

12.  Runge MS, Stouffer GA, Sheahan RG et al. Morphological patterns of death by myocytes in arrhythmogenic right ventricular dysplasia. Am J Med Sci 2000; 320:310-319.

13.  Nagata M, Hiroe M, Ishiyama S, et al. Apoptotic cell death in arrhythmogenic right ventircular cardiomoypathpy: a comparative study with idiopathic susptained ventricular tachycardia. Jpn Heart J 2000; 41: 733-741.

14. Villanova C. Arrhythmogenic right ventricular cardiomyopathy/dysplasia: echocardiographic features and criteria. Thesis Universita Degli Studi Di Padova Padua Italy December 1998.

15. Bluemke D, Krupinski EA, Ovitt T et al. MR Imaging of arrhythmogenic right ventircular cardiomyopathy: morphologic findings and interobserver reliability. Cardiology 2003 (In press).

16.  Frank R, Fontaine G, Vedel J et al: Electrocardiologie de quatre cas de dysplasia ventriculaire droite arythmogene. Arch Mal Coeur Vaiss 1978; 71: 963-972.

17.  Nava A, Canciani B, Buja GF et al. Electrovectorcardiographic study of negative T waves on precordial leads in arrhythmogenic right ventricular dysplasia: relationship with right ventricular volumes. J Electrocardiol 1988; 21: 239-245.

18. Fontaine G., Fontaliran F, Hebert JL et al. Arrhythmogenic right ventircular dysplasia. Annu Rev Med 1999; 50:17-35.

19. Nasir K, Rutberg J, Tandri H et al. Utility of SAECG in arrhythmogenic right ventricle dysplasia. ANE. 2003; 8:112-120.

20. Tonet JL, Castro-Miranda R, Iwa T, Poulain F, Frank R, Fontaine GH: Frequency of supraventricular tachyarrhythmias in arrhythmogenic right ventricular dysplasia. Am J Cardiol 1991; 67:1153.

21. Nakazato Y. Nakata Y. Tokano T. Ohno Y. Hisaoka T. Sumiyoshi M. Ogura S. Yamaguchi H. Kawai S. Okada R. et al. A case of arrhythmogenic right ventricular dysplasia with atrial flutter. Japanese Heart Journal. 1994; 35:689-94.

22.  Caglar N, Pamir G, Kural T, Candan I, Kumbasar A, Sonel A. Right ventricular cardiomypathy similar to Uhl's anomaly with atrial flutter and complete AV block. International J Cardiol 1993; 38: 199-201.

23. Lui CY. Marcus FI. Sobonya RE. Arrhythmogenic right ventricular dysplasia masquerading as peripartum cardiomyopathy with atrial flutter, advanced atrioventricular block and embolic stroke. Cardiology. 2002; 97:49-50.

24. Nava A, Bauce B, Basso C et al. Clinical profile and long-term follow-up of 37 families with arrhythmogenic right ventircular cardiomyopathy. J Am Coll Card 2000; 36:2226-33.

25. Hamid MS, Norman M, Quaraishi A et al. Prospective evaluation of relatives for familial arrhythmogenic right ventricular cardiomyopathy/dysplasia reveals a need to broaden diagnostic criteria. J Am Coll Card 2002; 40:1445-50.

26. Bauce B, Nava A, Rampazzo A, Daliento L, Muriago M, Basso C, Thiene G, Danieli A. Familial effort polymorphic ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy map to chromosome 1q42-43. Am J Cardiol 2000;85:573-579.

27. Rampazzo A, Nava A, Danieli GA, Buja G, Daliento L, Fasoli G, Scognamiglio R, Corrado D, Thiene G. The gene for arrhytmogenic right ventricular cardiomyopathy maps to chromosome 14q23-q24. Hum Mol Genet 1994; 3:959-962.

28.  Rampazzo A, Nava A, Miorin M, Fonderico P, Pope B, Tiso N, Livolsi B, Zimbello R, Thiene G, Danieli GA. ARVD4 a new locus for arrhythmogenic right ventricular cardiomyopathy maps to chromosome 2 long arm. Genomics 1997; 45:259-263.

29. Severini GM, Krajinovic M, Pinamonti B, Sinagra G, Fioretti P, Brunazzi MC, Falaschi A, Camerini G, Giacca M, Mestroni L. A new locus for arrhythmogenic right ventricular dysplasia on the long arm of chromosome 14. Genomics 1996; 31:193-200.

30. Ahmad F, Li D, Karibe A, Gonzales O, Tapscott T, Hill R, Weibaecher D, Blackie P, Furey M, Gardner M, Bachinski L, Roberts R. Localization of a gene responsible for arrhythmogenic right ventricular dysplasia to chromosome 3p23. Circulation 1998; 98:2791-2795.

31. Coonar AS, Protonotarios N, Tsatsopoulou A, Needham EW, Houlston RS, Cliff S, Otter MI, Murday VA, Mattu RK, McKenna WJ. Gene for arrythmogenic right ventricular cardiomyopathy with diffuse non epidermolytic palmoplantar keratoderma and wooly hair (Naxos disease) maps to 17q21. Circulation. 1998;97:2049-2058.

32. Bauce B, Nava A, Rampazzo A, Daliento L, Muriago M, Basso C, Thiene G, Danieli A. Familial effort polymorphic ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy map to chromosome 1q42-43. Am J Cardiol 2000;85:573-579.

33. Laitinen PJ Brown KM Piipo K et al. Mutations of the cardiac ryanodine receptor (RyR2) gene in familial polymorphic ventricular tachycardia. Circulation 2001; 103: 485-90.

34. Priori SG, Napolitano C, Tiso N et al. Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic vetnricular tachycardia. Cicrculation 2001; 103:196-200.

35. Norgett EE, Hatsell SJ, Carvajal-Guerta L et al. Recessive mutation in desmoplakin disrupts desmoplakin-intermediate filament interactions and causes dilated cardiomyopathy, wooly hair and keratoderma. Hum Mol Genetics 2000; 9: 2761-2766.

36. Grumbach IM, Heim A, Vonhof S, et al. Coxsackievirus genome in myocardium of patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. Cardiology 1998; 89: 241-5.

37. Bowles NE, Ni J, Marcus F, Towbin JA. The detection of cardiotropic viruses in the myocardium of patients with arrhythmogenic right ventircular dysplasia/cardiomyopathy. J Am Coll Card 2002; 39:892-5

38. Fontaine G, Fontaliran F, Rosas Andrade F, Velasquez E, Tonet J, Jouven X, Fujioka Y, Frank R. The arrhythmogenic right ventricle. Dysplasia versus cardiomyopathy. Heart Vessels 1995; 10:227-235.

39.  Thiene G, Corrado D, Nava A, et al. Right ventricular cardiomypathy: is there evidence of an inflammatory aetiology? Eur Heart J 1991; 12:22-25.

40.  Corrado D, Basso C, Thiene G, McKenna WJ, Davies MJ, Fontaliran F, Nava A, Silvestri F, Blomstrom-Lundqvist C, Wlodarska EK, Fontaine G, Camerini F. Spectrum of clinicopathologic manifestations of arrhythmogenic right ventricular cardiomypathy/dysplasia: A multicenter study. J Am Coll Cardiol 1997; 30: 1512-1520.

41. McKenna WJ, Thiene G, Nava A, Fontaliran F, Blomstrom-Lundqvist C, Fontaine G, Camerini F. Diagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Br Heart J 1994; 71:215-18.

42.  Nava A, Bauce B, Basso C et al. Clinical profile and long-term follow-up of 37 families with arrhythmogenic right ventircular cardiomyopathy. J Am Coll Card 2000; 36:2226-33.

43.  Hamid MS, Norman M, Quaraishi A et al. Prospective evaluation of relatives for familial arrhythmogenic right ventricular cardiomyopathy/dysplasia reveals a need to broaden diagnostic criteria. J Am Coll Card 2002; 40:1445-50.

44.  Wichter T, Hindricks G, Lerch H et al. Regional myocardial sympathetic dysinnervation in arrhythmogenic right ventricular cardiomyopathy: an analysis using 123I metaiodobenzylguanidine scintigraphy. Circulation 1994; 89: 667-83.

45. Marcus FI, Fontaine G. Arrhythmogenic right ventricular dysplasia/cardiomyopathy: a review. Pacing Clin Electrophysiol 1995; 18:1298-314

46. Guiraudon GM, Klein GJ, Gulamhusein SS, Painvin GA, Del Camp C, Gonzales JC, Ko PT. Total disconnection of the right ventricular free wall: surgical treatment of right ventricular tachycardia associated with right ventricular dysplasia. Circulation. 1983; 67: 463-470.

47.  Doig JC, Nimkhedkar K, Bourke JP, McComb JM, Hilton CJ, Furniss SS, Campbell RWF. Acute and chronic hemodynamic impact of total right ventricular disarticulation. PACE. 1991; 14:1971-1975.

48. Turrini P, Corrado D, Basso C et al. Noninvasive risk stratification in arrhythmogenic right ventricular cardiomyopathy. A.N.E. 2003; 8:161-169.

49. Dicks E, Hodgkinson K, Conners S. Initial clinical manifestations of arrhythmogenic right ventricular cardiomyopathy. Am J Hum Gen 2000; 67: 114a.

50. Scognamiglio R, Rahimtooia S, Thiene G, Nava A, Gasoli G, Daliento L, Buja G, Nistri S, Palisi M, Marin M, Dalla-Volta S. Concealed phase of familiar arrhythmogenic right ventricular cardiomyopathy (ARVD). Early recognition and long-term follow-up. J Am Coll Cardiol 1997; 29:194A.

51. Corrado D. Fontaine G. Marcus FI. McKenna WJ. Nava A. Thiene G. Wichter T. Arrhythmogenic right ventricular dysplasia/cardiomyopathy: need for an international registry. European Society of Cardiology and the Scientific Council on Cardiomyopathies of the World Heart Federation. Journal of Cardiovascular Electrophysiology. 2000; 11:827-32.

52. Gear, K and Marcus F. Arrhythmogenic right ventirculardysplasia/cardiomyopathy. Circulation 2003; 107:e31-33.

Home Page Current Issue List of Editors